On September 27, 2023 Flamingo Therapeutics ("Flamingo") reported that company management will participate at several upcoming investor and industry conferences in October 2023 (Press release, Flamingo Therapeutics, SEP 27, 2023, View Source;utm_medium=rss&utm_campaign=flamingo-therapeutics-announces-participation-at-upcoming-investor-and-industry-conferences [SID1234635452]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chardan 7th Annual Genetic Medicines Conference: October 2-3, 2023, in New York, USA
KBC Life Sciences Oncology Day: October 4, 2023, in Brussels, Belgium
BIO Japan: October 11-13, 2023, in Yokohama, Japan
3rd Annual Needham Private Biotech Company Virtual 1×1 Forum: October 17-18, 2023

During these conferences, Flamingo management will make presentations and are available to meet with potential investors and partners during one-on-one meetings.

On September 27, 2023 Eagle Pharmaceuticals presented its corporate presentation (Presentation, Eagle Pharmaceuticals, SEP 27, 2023, View Source [SID1234635451]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 27, 2023 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023 (Press release, CRISPR Therapeutics, SEP 27, 2023, View Source [SID1234635449]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CAR T cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency
Abstract Number: 274
Location: Exhibit Halls A and B1
Date and Time: Saturday, November 4, 2023, 9:00 a.m. – 8:30 p.m.

Title: Allogeneic CAR T cells targeting Liv-1 for Breast Cancer
Abstract Number: 324
Location: Exhibit Halls A and B1
Date and Time: Saturday, November 4, 2023, 9:00 a.m. – 8:30 p.m.

Title: Development of allogeneic, potency-edited, anti-GPC3 CAR-T cells for the treatment of hepatocellular carcinoma
Abstract Number: 264
Location: Exhibit Halls A and B1
Date and Time: Saturday, November 4, 2023, 9:00 a.m. – 8:30 p.m.

On September 27, 2023 Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), reported the presentation of three abstracts from its innovative immuno-oncology pipeline at the upcoming SITC (Free SITC Whitepaper) Annual Meeting taking place November 3 – 5, 2023 at the San Diego Convention Center in San Diego, CA (Press release, Coherus Biosciences, SEP 27, 2023, View Source [SID1234635448]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract #1351: Identifying IL-27 dependent biomarkers in lymphocytes, NK cells, and myeloid cells in peripheral blood and the tumor microenvironment
Date and Time: Friday, November 3, 9 a.m.–7 p.m. Pacific Daylight Time (PDT)
Location: Exhibit Halls A and B1 – San Diego Convention Center

Abstract #468: Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L-1 status
Date and Time: Saturday, November 4, 9 a.m.–8:30 p.m. PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center

Abstract #1354: Anti-CCR8 antibody SRF114 depletes tumor-infiltrating regulatory T cells in dissociated tumors from patients with head and neck squamous cell carcinoma
Date and Time: Saturday, November 4, 9 a.m.–8:30 p.m. PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center

On September 27, 2023 Cellectis (the "Company") (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 38th Annual Meeting (SITC 2023), that will take place on November 1-5, 2023 at San Diego Convention Center in San Diego (CA) (Press release, Cellectis, SEP 27, 2023, View Source [SID1234635447]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation:

Laurent Poirot, SVP Immunology of Cellectis, will present a poster on the benefits of combining potency attributes for TALEN-edited smart CAR T-cells targeting MUC1 in preclinical models of triple-negative breast cancer.

Title: TGF-Beta Blockade Combined with Activation-Induced IL12 Secretion Synergize to Optimize Potency of MUC1-CAR T-cells in Preclinical Targeting of Triple-Negative Breast Cancer.

Poster Number: 254

Presenter: Laurent Poirot, Ph.D., SVP Immunology, Cellectis.

Date/Time: Poster will be on display Saturday, November 4th, 2023 from 9:00 a.m. to 8:30 p.m. PDT, at San Diego Convention Center, Hall A.

Full text of the abstract will be made public on October 31, 2023 at 9:00 a.m. EDT on the SITC (Free SITC Whitepaper) website and in a Journal for ImmunoTherapy of Cancer (JITC) supplement published on Oct. 31st, 2023 at 6 a.m. PDT/9 a.m. EDT.